Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2–IN– 10];

12. Japanese Patent Application No. 2020–517556 effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2–JP– 11];

13. Korean Patent Application No. 2020–7012344 effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2–KR– 12];

14. Mexican Application No. MX/a/ 2020/003504, effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2– MX–13];

15. New Zealand Patent Application No. 763023 effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2– NZ–14];

16. Singapore Patent Application No. 11202002636P effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2–SG– 15];

17. United States Patent Application No. 16/651,242 effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2–US– 16];

18. Hong Kong Patent Application No. 62020021272.3 effective filing date of September 17, 2018 entitled "T Cell Receptors Recognizing Mutated P53" [HHS Reference No. E–237–2017–2– HK–17];

19. United States Provisional Patent Application No. 62/867,619, filed June 27, 2019 entitled "T Cell Receptors Recognizing R175H or Y220C Mutation in P53" [HHS Reference No. E–135– 2019–0–US–01];

20. PCT Application No. PCT/ US2020/039785, filed June 26, 2020 entitled "T Cell Receptors Recognizing R175H or Y220C Mutation in P53" [HHS Reference No. E–135–2019–0– PCT–02];

21. Taiwanese Application No. 109121744, filed June 26, 2020 entitled "T Cell Receptors Recognizing R175H or Y220C Mutation in P53" [HHS Reference No. E–135–2019–0–TW–03];

22. United States Provisional Patent Application No. 63/074,747, filed September 4, 2020 entitled "T Cell Receptors Recognizing R273C or Y220C Mutation in P53" [HHS Reference No. E-173-2020-0-US-01]; 23. PCT Patent Application No. PCT/ US2021/048786, filed September 2, 2021 entitled "T Cell Receptors Recognizing R273C or Y220C Mutation in P53" [HHS Reference No. E–173– 2020–0–PCT–02]; and

24. Taiwanese Patent Application No. "TBD", filed September 2, 2021 entitled "T Cell Receptors Recognizing R273C or Y220C Mutation in P53" [HHS Reference No. E–173–2020–0–TW–03].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

"Autologous T cell therapy products engineered by use of a CRISPR-nuclease to express a therapeutic T cell receptor claimed in the Licensed Patent Rights for the treatment or prevention of cancer in humans"

"Allogeneic T cell therapy products engineered by use of a CRISPR-nuclease to express a therapeutic T cell receptor claimed in the Licensed Patent Rights for the treatment or prevention of cancer in humans"

Specifically excluded from these fields of use are:

1. Autologous, peripheral blood T cell therapy products engineered by transposon-mediated gene transfer for the treatment of human cancers;

2. Autologous, peripheral blood T cell therapy products engineered via retrovirus and lentivirus-mediated gene transfer for the treatment of human cancer: and

3. Natural Killer T (NKT) cell therapy products engineered via viral and nonviral means for the treatment of human cancers. Wherein the NKT cell therapy product contains at least 50% NKT cells.

Intellectual Property Group A is primarily directed to isolated T cell receptors (TCRs) reactive to mutated Kirsten rat sarcoma viral oncogene homolog (KRAS), within the context of several human leukocyte antigens (HLAs). Mutated KRAS, which plays a well-defined driver role in oncogenesis, is expressed by a variety of human cancers, including pancreatic, lung, endometrial, ovarian and prostate. Due to its restricted expression in precancerous and cancerous cells, this antigen may be targeted on mutant KRAS-expressing tumors with minimal normal tissue toxicity.

Intellectual Property Group B is primarily directed to isolated TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the context of several HLAs. *P53* is the archetypal tumor suppressor gene and the most frequently mutated gene in cancer. Contemporary estimates suggest that >50% of all tumors carry mutations in *P53.* Because of its prevalence in cancer and its restricted expression to precancerous and cancerous cells, this antigen may be targeted on mutant P53expressing tumors with minimal normal tissue toxicity.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 21, 2021.

#### Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2021–23289 Filed 10–25–21; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HOMELAND SECURITY

# Federal Emergency Management Agency

[Docket ID FEMA-2008-0010]

# Board of Visitors for the National Fire Academy; Meeting

**AGENCY:** Federal Emergency Management Agency, DHS.

**ACTION:** Committee management; notice of open Federal Advisory Committee meeting.

**SUMMARY:** The Board of Visitors for the National Fire Academy (Board) will meet virtually on Monday, December 6, 2021. The meeting will be open to the public.

**DATES:** The meeting will take place on Monday, December 6, 2021, 3:00 p.m. to 5:00 p.m. EST. Please note that the meeting may close early if the Board has completed its business.

ADDRESSES: Members of the public who wish to participate in the virtual conference should contact Deborah Gartrell-Kemp as listed in the FOR FURTHER INFORMATION CONTACT section by close of business on November 22, 2021, to obtain the call-in number and access code for the December 6th virtual meeting. For more information on services for individuals with disabilities or to request special assistance, contact Deborah Gartrell-Kemp as soon as possible.

To facilitate public participation, we are inviting public comment on the issues to be considered by the Board as listed in the SUPPLEMENTARY **INFORMATION** section. Participants seeking to have their comments considered during the meeting should submit them in advance or during the public comment segment. Comments submitted up to 30 days after the meeting will be included in the public record and may be considered at the next meeting. Comments submitted in advance must be identified by Docket ID FEMA-2008-0010 and may be submitted by *one* of the following

methods: • Federal eRulemaking Portal: http://

*www.regulations.gov.* Follow the instructions for submitting comments.

• *Electronic Delivery:* Email Deborah Gartrell-Kemp at *Deborah.GartrellKemp@fema.dhs.gov* no later than December 1, 2021, for consideration at the December 6, 2021 meeting.

Instructions: All submissions received must include the words "Federal Emergency Management Agency" and the Docket ID for this action. Comments received will be posted without alteration at http://www.regulations.gov, including any personal information provided.

Docket: For access to the docket to read background documents or comments received by the National Fire Academy Board of Visitors, go to http:// www.regulations.gov, click on "Advanced Search," then enter

"FEMA–2008–0010" in the "By Docket ID" box, then select "FEMA" under "By Agency," and then click "Search."

# FOR FURTHER INFORMATION CONTACT:

Alternate Designated Federal Officer: Stephen Dean, telephone (301) 447– 1271, email Stephen.Dean@ fema.dhs.gov.

*Logistical Information:* Deborah Gartrell-Kemp, telephone (301) 447– 7230, email Deborah.GartrellKemp@ fema.dhs.gov.

**SUPPLEMENTARY INFORMATION:** The Board will meet virtually on Monday, December 6, 2021. The meeting will be open to the public. Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. Appendix.

#### **Purpose of the Board**

The purpose of the Board is to review annually the programs of the National Fire Academy (Academy) and advise the Administrator of the Federal Emergency Management Agency (FEMA), through the United States Fire Administrator, on the operation of the Academy and any improvements therein that the Board deems appropriate. In carrying out its responsibilities, the Board examines Academy programs to determine whether these programs further the basic missions that are approved by the Administrator of FEMA, examines the physical plant of the Academy to determine the adequacy of the Academy's facilities, and examines the funding levels for Academy programs. The Board submits a written annual report through the United States Fire Administrator to the Administrator of FEMA. The report provides detailed comments and recommendations regarding the operation of the Academy.

#### Agenda

On Monday, December 6, 2021, there will be five sessions, with deliberations and voting at the end of each session as necessary:

1. The Board will present their Annual BOV report.

2. The Board will discuss United States Fire Administration Data, Research, Prevention and Response.

3. The Board will discuss deferred maintenance and capital improvements on the National Emergency Training Center campus and Fiscal Year 2022 Budget Request/Budget Planning.

4. The Board will deliberate and vote on recommendations on Academy program activities to include developments, deliveries, staffing, admissions and strategic plan.

5. There will also be an update on the Board of Visitors Subcommittee Groups for the Professional Development Initiative Update and the National Fire Incident Report System.

There will be a 10-minute comment period after each agenda item and each speaker will be given no more than 2 minutes to speak. Please note that the public comment period may end before the time indicated following the last call for comments. Contact Deborah GartrellKemp to register as a speaker. Meeting materials will be posted at *https:// www.usfa.fema.gov/training/nfa/about/ bov.html* by December 1, 2021.

# Eriks J. Gabliks,

Superintendent, National Fire Academy, United States Fire Administration, Federal Emergency Management Agency. [FR Doc. 2021–23300 Filed 10–25–21; 8:45 am]

BILLING CODE 9111-74-P

# DEPARTMENT OF HOMELAND SECURITY

# Federal Emergency Management Agency

[Docket ID FEMA-2021-0002; Internal Agency Docket No. FEMA-B-2175]

#### Changes in Flood Hazard Determinations

**AGENCY:** Federal Emergency Management Agency, DHS. **ACTION:** Notice.

**SUMMARY:** This notice lists communities where the addition or modification of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or the regulatory floodway (hereinafter referred to as flood hazard determinations), as shown on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports, prepared by the Federal Emergency Management Agency (FEMA) for each community, is appropriate because of new scientific or technical data. The FIRM, and where applicable, portions of the FIS report, have been revised to reflect these flood hazard determinations through issuance of a Letter of Map Revision (LOMR), in accordance with Federal Regulations. The currently effective community number is shown in the table below and must be used for all new policies and renewals.

**DATES:** These flood hazard determinations will be finalized on the dates listed in the table below and revise the FIRM panels and FIS report in effect prior to this determination for the listed communities.

From the date of the second publication of notification of these changes in a newspaper of local circulation, any person has 90 days in which to request through the community that the Deputy Associate Administrator for Insurance and Mitigation reconsider the changes. The flood hazard determination information